Moderna’s mRESVIA Vaccine Faces Market Challenges Despite FDA Approval

Geoff Meacham, an analyst from Citi, maintained the Hold rating on Moderna (MRNA – Research Report). The associated price target remains the same with $32.00.

Geoff Meacham has given his Hold rating due to a combination of factors impacting Moderna’s stock. The recent FDA approval for Moderna’s mRESVIA vaccine to treat high-risk adults aged 18-59 expands its market reach beyond the previous ≥60 age group. However, despite this expansion, the overall low vaccination rates for RSV in the United States present a significant challenge to market growth.
Furthermore, the lack of a recommendation for re-vaccination from the relevant committee limits the potential for increased demand. Additionally, pending policy decisions for high-risk individuals under 50 years old add uncertainty to the market outlook. The recent changes in the advisory committee members, who are perceived to hold more skeptical views, also contribute to the cautious stance. As a result, Meacham maintains a Neutral rating with a target price of $32.

MRNA’s price has also changed moderately for the past six months – from $41.830 to $26.670, which is a -36.24% drop .